NEW YORK (GenomeWeb News) — Epigenomics today said second-quarter revenue fell 17 percent as R&D spending rose 17 percent and net loss decreased 21 percent.
 
Total receipts for the three months ended June 30 fell to €524,000 ($718,000) from €628,000 year over year.
 
The company said €511,000 of its €1.3 million total half-year revenue came from residuals from a collaboration with Roche Diagnostics, which officially ended in March.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.